according to the OSHA Hazard Communication Standard



# **Oxytocin Formulation**

Version Revision Date: SDS Number: Date of last issue: 01/29/2024 2.11 09/28/2024 3447264-00014 Date of first issue: 09/26/2018

#### **SECTION 1. IDENTIFICATION**

Product name : Oxytocin Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc Address : 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product Restrictions on use : Not applicable

#### **SECTION 2. HAZARDS IDENTIFICATION**

# GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Not a hazardous substance or mixture.

# **GHS** label elements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

### Other hazards

None known.

#### SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

#### Components

Chemical name	CAS-No.	Concentration (% w/w)
Oxytocin, monoacetate (salt)	6233-83-6	< 0.1

Actual concentration is withheld as a trade secret

### **SECTION 4. FIRST AID MEASURES**

If inhaled : If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

: Wash with water and soap as a precaution.

In case of skin contact : Wash with water and soap as a precaution

Get medical attention if symptoms occur. Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur.

Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and

In case of eye contact

delayed

None known.

according to the OSHA Hazard Communication Standard



# **Oxytocin Formulation**

Version Revision Date: SDS Number: Date of last issue: 01/29/2024 2.11 09/28/2024 3447264-00014 Date of first issue: 09/26/2018

Protection of first-aiders : No special precautions are necessary for first aid responders.

Notes to physician : Treat symptomatically and supportively.

#### **SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod- :

ucts

No hazardous combustion products are known

Specific extinguishing meth-

ode

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for fire-fighters

Wear self-contained breathing apparatus for firefighting if

necessary.

Use personal protective equipment.

#### **SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emer-

gency procedures

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g., by containment or

oil barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Soak up with inert absorbent material.

For large spills, provide diking or other appropriate

containment to keep material from spreading. If diked material

can be pumped, store recovered material in appropriate

container.

Clean up remaining materials from spill with suitable

absorbent.

Local or national regulations may apply to releases and

according to the OSHA Hazard Communication Standard



# **Oxytocin Formulation**

Version Revision Date: SDS Number: Date of last issue: 01/29/2024 2.11 09/28/2024 3447264-00014 Date of first issue: 09/26/2018

disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

#### **SECTION 7. HANDLING AND STORAGE**

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Handle in accordance with good industrial hygiene and safety

practice, based on the results of the workplace exposure

assessment

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labeled containers.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Gases

# **SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**

#### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Oxytocin, monoacetate (salt)	6233-83-6	STEL	50 ng/m3 (OEB 5)	Internal
		Wipe limit	500 ng/100 cm <sup>2</sup>	Internal

**Engineering measures** : Use closed processing systems or containment technologies

to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

No open handling permitted.

Totally enclosed processes and materials transport systems

are required.

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into

the workplace.

Personal protective equipment

Respiratory protection : No personal respiratory protective equipment normally

required.

Hand protection

Material : Chemical-resistant gloves

according to the OSHA Hazard Communication Standard



# **Oxytocin Formulation**

Version Revision Date: SDS Number: Date of last issue: 01/29/2024 2.11 09/28/2024 3447264-00014 Date of first issue: 09/26/2018

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

#### **SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance : liquid

Color : No data available

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

according to the OSHA Hazard Communication Standard



# **Oxytocin Formulation**

Version Revision Date: SDS Number: Date of last issue: 01/29/2024 2.11 09/28/2024 3447264-00014 Date of first issue: 09/26/2018

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : Not applicable

#### **SECTION 10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

Can react with strong oxidizing agents.

Conditions to avoid : None known.
Incompatible materials : Oxidizing agents

Hazardous decomposition : No hazardous decomposition products are known.

products

#### **SECTION 11. TOXICOLOGICAL INFORMATION**

#### Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

### **Acute toxicity**

Not classified based on available information.

according to the OSHA Hazard Communication Standard



# **Oxytocin Formulation**

Version Revision Date: SDS Number: Date of last issue: 01/29/2024 2.11 09/28/2024 3447264-00014 Date of first issue: 09/26/2018

### **Components:**

Oxytocin, monoacetate (salt):

Acute oral toxicity : LD50 (Mouse): > 514 mg/kg

LD50 (Rat): > 21 mg/kg

Acute toxicity (other routes of :

administration)

LD50 (Mouse): > 514 mg/kg Application Route: Subcutaneous

LD50 (Mouse): 5.8 mg/kg Application Route: Intravenous

LD50 (Rat): > 21 mg/kg

Application Route: Subcutaneous

LD50 (Rat): 2.3 mg/kg

Application Route: Intravenous

#### Skin corrosion/irritation

Not classified based on available information.

#### Serious eye damage/eye irritation

Not classified based on available information.

#### Respiratory or skin sensitization

#### Skin sensitization

Not classified based on available information.

#### Respiratory sensitization

Not classified based on available information.

### Germ cell mutagenicity

Not classified based on available information.

#### Components:

## Oxytocin, monoacetate (salt):

Genotoxicity in vitro : Test Type: Chromosomal aberration

Test system: Human lymphocytes

Result: negative

### Carcinogenicity

Not classified based on available information.

IARC No ingredient of this product present at levels greater than or equal to 0.1% is

identified as probable, possible or confirmed human carcinogen by IARC.

**OSHA**No component of this product present at levels greater than or equal to 0.1% is

on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is

identified as a known or anticipated carcinogen by NTP.

according to the OSHA Hazard Communication Standard



# **Oxytocin Formulation**

Version Revision Date: SDS Number: Date of last issue: 01/29/2024 2.11 09/28/2024 3447264-00014 Date of first issue: 09/26/2018

### Reproductive toxicity

Not classified based on available information.

### **Components:**

#### Oxytocin, monoacetate (salt):

Effects on fetal development : Test Type: Development

Species: Rat

Application Route: Subcutaneous

Developmental Toxicity: NOAEL: 1 mg/kg body weight

Result: No effects on fetal development.

Reproductive toxicity - As-

sessment

May damage the unborn child.

### STOT-single exposure

Not classified based on available information.

#### STOT-repeated exposure

Not classified based on available information.

#### Repeated dose toxicity

#### **Components:**

#### Oxytocin, monoacetate (salt):

Exposure time : 5 Days

Target Organs : Endocrine system

#### **Aspiration toxicity**

Not classified based on available information.

#### **Experience with human exposure**

### **Components:**

# Oxytocin, monoacetate (salt):

Inhalation : Target Organs: Central nervous system

Symptoms: behavioral abnormalities Target Organs: Cardio-vascular system

Symptoms: Increased heart rate, May cause cardiac arrhyth-

mia., hypotension, tachycardia, flushing Target Organs: Gastrointestinal tract

Symptoms: Nausea, Vomiting

Ingestion : Target Organs: Central nervous system

Symptoms: behavioral abnormalities Target Organs: Cardio-vascular system

Symptoms: Increased heart rate, May cause cardiac arrhyth-

mia., hypotension, tachycardia, flushing Target Organs: Gastrointestinal tract

Symptoms: Nausea, Vomiting

according to the OSHA Hazard Communication Standard



# **Oxytocin Formulation**

Version Revision Date: SDS Number: Date of last issue: 01/29/2024 2.11 09/28/2024 3447264-00014 Date of first issue: 09/26/2018

#### **SECTION 12. ECOLOGICAL INFORMATION**

#### **Ecotoxicity**

#### Components:

#### Oxytocin, monoacetate (salt):

### **Ecotoxicology Assessment**

Acute aquatic toxicity : Toxic effects cannot be excluded

Chronic aquatic toxicity : Toxic effects cannot be excluded

#### Persistence and degradability

No data available

**Bioaccumulative potential** 

#### **Components:**

# Oxytocin, monoacetate (salt):

Partition coefficient: n-

octanol/water

log Pow: 6.27

# Mobility in soil

No data available

#### Other adverse effects

No data available

# **SECTION 13. DISPOSAL CONSIDERATIONS**

#### **Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

#### **SECTION 14. TRANSPORT INFORMATION**

### **International Regulations**

# **UNRTDG**

Not regulated as a dangerous good

#### IATA-DGR

Not regulated as a dangerous good

#### **IMDG-Code**

Not regulated as a dangerous good

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

according to the OSHA Hazard Communication Standard



# **Oxytocin Formulation**

Version Revision Date: SDS Number: Date of last issue: 01/29/2024 2.11 09/28/2024 3447264-00014 Date of first issue: 09/26/2018

### **Domestic regulation**

**49 CFR** 

Not regulated as a dangerous good

Special precautions for user

Not applicable

#### **SECTION 15. REGULATORY INFORMATION**

# **CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

### SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

# SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : No SARA Hazards

SARA 313 : This material does not contain any chemical components with

known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

## **US State Regulations**

### Pennsylvania Right To Know

Water 7732-18-5

# The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

#### **SECTION 16. OTHER INFORMATION**

#### **Further information**


according to the OSHA Hazard Communication Standard



# **Oxytocin Formulation**

Version Revision Date: SDS Number: Date of last issue: 01/29/2024 2.11 09/28/2024 3447264-00014 Date of first issue: 09/26/2018

#### NFPA 704:



Special hazard

#### HMIS® IV:



HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "\*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

#### Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC -International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory: TECI - Thailand Existing Chemicals Inventory: TSCA - Toxic Substances Control Act

according to the OSHA Hazard Communication Standard



# **Oxytocin Formulation**

Version **Revision Date:** SDS Number: Date of last issue: 01/29/2024 2.11 09/28/2024 3447264-00014 Date of first issue: 09/26/2018

(United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety

**Data Sheet** 

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

**Revision Date** 09/28/2024

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8